The Gut Barrier Protocol — BPC-157 + KPV
A targeted peptide protocol combining BPC-157 and KPV for comprehensive gut barrier restoration. BPC-157 rebuilds mucosal structure via growth factor pathways; KPV suppresses intestinal inflammation via MC1R signalling. Designed for leaky gut, IBD, post-antibiotic dysbiosis, and SIBO recovery.
Daily Schedule
Timing and dosage for each step
08:00 AM
500 mcg
Oral BPC-157 capsule with breakfast. For gut-targeted effects, oral route concentrates peptide in GI tract. Take with food.
08:00 AM
2 mg
KPV capsule with breakfast. Enteric-coated if available. Oral route preferred for gut-localised anti-inflammatory effect.
06:00 PM
06:00 PM
Protocol Overview
The gut barrier is the interface between the external world and your bloodstream. When compromised — by antibiotics, NSAIDs, alcohol, stress, or autoimmune activity — increased intestinal permeability drives systemic inflammation, food sensitivities, and impaired nutrient absorption.
This protocol uses two peptides with complementary mechanisms to address gut repair simultaneously from structural and inflammatory angles.
BPC-157 (Body Protection Compound) promotes healing via VEGF upregulation and growth factor signalling — rebuilding the mucosal lining and improving local blood supply.
KPV (Lys-Pro-Val) suppresses gut inflammation via MC1R activation — reducing NF-κB, lowering TNF-α and IL-1β, and polarising macrophages toward a repair phenotype.
Who This Protocol Is For
- Leaky gut / intestinal hyperpermeability
- Inflammatory bowel disease (Crohn's, ulcerative colitis) — adjunctive to medical treatment
- Post-antibiotic dysbiosis and gut damage
- SIBO (Small Intestinal Bacterial Overgrowth) recovery
- NSAID or alcohol-related gut damage
- Food sensitivity driven by gut permeability
Oral vs. Subcutaneous Administration
For gut-targeted effects, oral administration is preferred. Oral BPC-157 and KPV concentrate the peptides in the gastrointestinal tract rather than distributing systemically. Use enteric-coated capsules where available to improve small intestinal delivery.
Subcutaneous BPC-157 may be added for systemic repair effects in severe cases.
Protocol Duration
Acute phase (Weeks 1–8): Full protocol as described
Maintenance (Weeks 9–12): BPC-157 once daily, KPV once daily
Assessment: Symptom tracking + optional biomarkers (zonulin, calprotectin, LPS-binding protein)
Supporting Interventions
- Eliminate gut irritants: NSAIDs, alcohol, refined sugars during protocol
- Prebiotic/probiotic support: Akkermansia muciniphila, Lactobacillus rhamnosus GG
- L-glutamine 5g/day: additional mucosal substrate
- Zinc carnosine 75mg/day: synergistic gut barrier support
Disclaimer
BPC-157 and KPV are research peptides not approved by the FDA or EMA. This protocol is for educational purposes only.